Rate Of ReturnEli Lilly continues to benefit from strong demand for its diabetes and weight-loss treatments, which have become major growth drivers. The company also has a promising pipeline that could support future earnings growth. However, the stock trades at a premium valuation, meaning investors are expecting continued success in both its current products and future drug development efforts.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
